EyePoint Pharmaceuticals, Inc. (EYPT)

EyePoint Pharmaceuticals, Inc. (EYPT) Healthcare & Pipeline Overview

EyePoint Pharmaceuticals, Inc. develops and commercializes innovative ophthalmic solutions, including ILUVIEN, YUTIQ, and DEXYCU, addressing significant unmet needs in diabetic macular edema, uveitis, and post-operative ocular inflammation. The company leverages sustained-release technology and strategic collaborations to expand its market reach and product pipeline within the biotechnology sector.

What Is the Investment Thesis for EYPT?

EyePoint Pharmaceuticals, Inc. presents a compelling investment thesis based on its established portfolio of ophthalmic products and promising pipeline. The company's revenue is driven by sales of ILUVIEN, YUTIQ, and DEXYCU, addressing significant markets in DME, uveitis, and post-operative inflammation. The development of EYP-1901, a twice-yearly treatment for wet AMD, DR, and RVO, represents a substantial growth catalyst, potentially capturing a significant share of the multi-billion dollar market. While EyePoint's gross margin stands at 76.5%, its negative profit margin of -3566.6% indicates ongoing investments in R&D and commercialization. Successful clinical trials and regulatory approvals for EYP-1901 are critical for future growth. Potential risks include competition from established players, regulatory hurdles, and the inherent uncertainty in drug development timelines.

Based on FMP financials and quantitative analysis

EYPT Key Highlights

• Market capitalization of $1.20B reflects investor confidence in EyePoint's ophthalmic product portfolio and pipeline.
• Gross margin of 76.5% indicates strong pricing power and efficient manufacturing processes.
• Negative profit margin of -3566.6% highlights ongoing investments in research and development, particularly for EYP-1901.
• Strategic collaborations with Alimera Sciences, Bausch & Lomb, and Ocumension Therapeutics expand market reach and product development capabilities.
• Development of EYP-1901, a twice-yearly treatment for wet AMD, DR, and RVO, represents a significant growth opportunity in a multi-billion dollar market.

Who Are EYPT's Competitors?

EYPT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EYPT's Key Strengths?

• Innovative sustained-release drug delivery technology.
• Established product portfolio with multiple FDA-approved products.
• Strategic collaborations with leading pharmaceutical companies.
• Strong intellectual property protection.

What Are EYPT's Weaknesses?

• Negative profit margin due to high R&D and commercialization costs.
• Reliance on a limited number of products for revenue generation.
• Competition from established players in the ophthalmic market.
• Potential regulatory hurdles for new product approvals.

What Could Drive EYPT Stock Higher?

• Clinical trial results for EYP-1901 in wet AMD, DR, and RVO are expected in the next 12-18 months.
• Potential FDA approval of EYP-1901 for wet AMD, DR, and RVO could occur within the next 2-3 years.
• Continued growth in sales of ILUVIEN, YUTIQ, and DEXYCU is expected to drive revenue growth.
• Expansion of strategic collaborations to expand market reach and product development.

What Are the Key Risks for EYPT?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from established players in the ophthalmic market.
• Regulatory hurdles for new product approvals.
• Product liability claims.
• Negative profit margin due to high R&D and commercialization costs.
• Reliance on a limited number of products for revenue generation.

What Are the Growth Opportunities for EYPT?

• Expansion of EYP-1901 into Wet AMD Market: EYP-1901, a twice-yearly bioerodible formulation of a tyrosine kinase inhibitor, targets wet age-related macular degeneration (AMD). The global wet AMD market is projected to reach $12 billion by 2028. Successful clinical trials and regulatory approval could position EYP-1901 as a leading treatment, capturing a significant market share. This represents a substantial revenue opportunity for EyePoint.
• Penetration into Diabetic Retinopathy (DR) Market with EYP-1901: Diabetic retinopathy is a major cause of vision loss in diabetic patients. EYP-1901 is also being developed for DR, addressing a market projected to reach $4.9 billion by 2027. If approved, EYP-1901 could offer a convenient, less frequent treatment option compared to existing therapies, driving adoption and revenue growth for EyePoint.
• Growth in Retinal Vein Occlusion (RVO) Market with EYP-1901: Retinal vein occlusion is another significant cause of vision impairment. The RVO market is expected to grow to $1.5 billion by 2025. The development of EYP-1901 for RVO provides EyePoint with an opportunity to expand its product portfolio and address an unmet need in this market segment, contributing to overall revenue growth.
• Geographic Expansion into China with Ocumension Therapeutics Collaboration: EyePoint has a strategic collaboration with Ocumension Therapeutics to develop and commercialize its products in China. The Chinese market for ophthalmic treatments is rapidly growing, driven by increasing healthcare spending and an aging population. This collaboration provides EyePoint with access to a large and underserved market, driving international revenue growth.
• Increased Adoption of DEXYCU for Post-Operative Ocular Inflammation: DEXYCU is a dexamethasone intraocular suspension used for the treatment of post-operative ocular inflammation following cataract surgery. The market for post-operative inflammation treatments is growing, driven by the increasing number of cataract surgeries performed annually. Increased adoption of DEXYCU, driven by physician awareness and positive clinical outcomes, represents a growth opportunity for EyePoint.

What Opportunities Does EYPT Have?

• Expansion of EYP-1901 into wet AMD, DR, and RVO markets.
• Geographic expansion into China and other international markets.
• Development of new ophthalmic products using sustained-release technology.
• Increased adoption of DEXYCU for post-operative ocular inflammation.

What Threats Does EYPT Face?

• Competition from generic drugs and biosimilars.
• Unfavorable regulatory changes.
• Product liability claims.
• Economic downturn affecting healthcare spending.

What Are EYPT's Competitive Advantages?

• Sustained-release drug delivery technology reduces the frequency of injections.
• Established product portfolio with ILUVIEN, YUTIQ, and DEXYCU.
• Strong intellectual property protection for its products and technologies.
• Strategic collaborations with leading pharmaceutical companies.

What Does EYPT Do?

EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts. Initially known as pSivida Corp., the company rebranded to EyePoint Pharmaceuticals, Inc. in March 2018, reflecting its sharpened focus on ophthalmic solutions. EyePoint specializes in developing and commercializing innovative treatments for eye diseases, utilizing sustained-release drug delivery systems. The company's product portfolio includes ILUVIEN, an injectable sustained-release micro-insert for diabetic macular edema (DME); YUTIQ, a fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension for post-operative ocular inflammation, particularly following cataract surgery. EyePoint is also advancing its pipeline with EYP-1901, a twice-yearly bioerodible formulation of a tyrosine kinase inhibitor targeting wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO), as well as YUTIQ50 for uveitis. EyePoint has established strategic collaborations with companies like Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC, to expand its market presence and develop new products. Additionally, it has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU. EyePoint's focus on sustained-release technology aims to improve patient outcomes by reducing the frequency of injections and providing consistent drug delivery to the eye.

What Products and Services Does EYPT Offer?

• Develop and commercialize ophthalmic products for eye diseases.
• Provide ILUVIEN, an injectable sustained-release micro-insert for diabetic macular edema.
• Offer YUTIQ, a fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
• Market DEXYCU, a dexamethasone intraocular suspension for post-operative ocular inflammation.
• Develop EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for wet AMD, DR, and RVO.
• Engage in strategic collaborations with other pharmaceutical companies to expand market reach and product development.

How Does EYPT Make Money?

• Develop and obtain regulatory approval for ophthalmic drugs.
• Manufacture and market these drugs directly or through partnerships.
• Generate revenue through product sales to healthcare providers and patients.
• Establish strategic collaborations to expand market reach and product development.

What Industry Does EYPT Operate In?

EyePoint Pharmaceuticals, Inc. operates in the biotechnology industry, specifically focusing on ophthalmic solutions. The market for eye disease treatments is substantial and growing, driven by an aging population and increasing prevalence of conditions like diabetic macular edema, age-related macular degeneration, and glaucoma. The competitive landscape includes established pharmaceutical companies and specialized biotech firms. EyePoint differentiates itself through its sustained-release drug delivery technology, aiming to reduce the frequency of injections and improve patient compliance. The global ophthalmology market is projected to reach billions of dollars by 2028, presenting significant opportunities for companies with innovative products.

Who Are EYPT's Key Customers?

• Ophthalmologists and retinal specialists.
• Hospitals and surgical centers.
• Pharmacies and distributors.
• Patients with eye diseases such as diabetic macular edema, uveitis, and age-related macular degeneration.

FY2026 estForward Outlook

Wall Street analysts project EyePoint Pharmaceuticals, Inc. revenue of about $1.7M for fiscal 2026, with EPS near $-3.53. The estimate reflects 9 contributing analysts.

F-Score 1/9Financial Health

EyePoint Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.30 places it in the safe zone, indicating low near-term bankruptcy risk.

Key Financial Metrics

Return on assets is -94.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -22.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.1%, the inverse of the P/E and a quick read on earnings relative to price.

EyePoint Pharmaceuticals, Inc. (EYPT) Valuation Context

Valued at $1.20B, EYPT is classified as a small-cap stock. Relative to its peer group, EYPT's quantitative score of 18/100 is below the peer average of 78/100.

Company Profile

EyePoint Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Jay S. Duker. EYPT has traded publicly since 2005.

EYPT Financials

EYPT Latest News

EYPT Analyst Consensus

EYPT MoonshotScore

EYPT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources